Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
3.01 USD -3.83% Intraday chart for Century Therapeutics, Inc. -3.83% -9.34%
May. 10 Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting CI
May. 09 Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Century Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2ff0ad.JeiF_H9-CE1MXZ2UNX2KYOiVAqvPOWQkKNAU7kEZNrw.dpmzmz4WOB8BCtbtWUu4LLLWSun7YxBHboYmnTMqBs1TkOuwBzdkCwsupQ~4d2a62bb8a605ffadb7ec3434f5a825d

Analyst Recommendations on Century Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating MT
Canaccord Genuity Adjusts Price Target on Century Therapeutics to $24 From $22, Maintains Buy Rating MT
JPMorgan Downgrades Century Therapeutics to Neutral From Overweight, Adjusts Price Target to $5 From $28 MT
HC Wainwright Adjusts Century Therapeutics' Price Target to $13 From $17, Keeps Buy Rating MT
Chardan Adjusts Price Target on Century Therapeutics to $17 From $19, Keeps Buy Rating MT
HC Wainwright Trims Price Target on Century Therapeutics to $17 From $19, Maintains Buy Rating MT
SVB Securities Adjusts Century Therapeutics' Price Target to $14 From $20, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Century Therapeutics to $19 From $25, Maintains Buy Rating MT
Piper Sandler Adjusts Century Therapeutics Price Target to $14 From $24, Maintains Overweight Rating MT
EF Hutton Initiates Century Therapeutics at Buy With $18 Price Target MT
Chardan Initiates Century Therapeutics With Buy Rating, $19 Price Target MT
Guggenheim Initiates Century Therapeutics at Buy With $15 Price Target MT
Canaccord Genuity Initiates Century Therapeutics at Buy with $28 Price Target MT
HC Wainwright Starts Century Therapeutics at Buy With $27 Price Target MT
Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Overweight Rating MT
William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating MT
SVB Leerink Adjusts Century Therapeutics' Price Target to $27 from $32, Keeps Outperform Rating MT
SVB Leerink Adjusts Century Therapeutics' Price Target to $32 from $33, Keeps Outperform Rating MT
CENTURY THERAPEUTICS : SVB Leerink Initiates Coverage on Century Therapeutics With Outperform Rating, $33 Price Target MT
CENTURY THERAPEUTICS : JPMorgan Starts Century Therapeutics at Overweight With $40 Price Target MT
CENTURY THERAPEUTICS : BofA Securities Starts Century Therapeutics at Buy With $34 Price Target MT
CENTURY THERAPEUTICS : Piper Sandler Starts Century Therapeutics at Overweight With $38 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.01 USD
Average target price
14.17 USD
Spread / Average Target
+370.65%
High Price Target
24 USD
Spread / Highest target
+697.34%
Low Price Target
9 USD
Spread / Lowest Target
+199.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Century Therapeutics, Inc.

Piper Sandler
Canaccord Genuity
JPMorgan Chase
HC Wainwright
Chardan Research
SVB Securities LLC
EF Hutton
Guggenheim
William Blair & Co.
SVB Leerink
BofA Securities

Ratings for Century Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. Consensus Century Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW